2021 U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration August 3, 2021 Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease July 24, 2021 Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at the 2021 ASCRS ASOA Annual Meeting July 19, 2021 William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directors June 22, 2021 Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meeting April 27, 2021 View prior press releases
